Orimeten
Orimeten Brand names, Orimeten Analogs
Orimeten Brand Names Mixture
- No information avaliable
Orimeten Chemical_Formula
C13H16N2O2
Orimeten RX_link
http://www.rxlist.com/cgi/generic3/cytadren.htm
Orimeten fda sheet
Orimeten msds (material safety sheet)
Orimeten Synthesis Reference
Hoffmann, Urech, U.S. pat. 2,848,455 (1958 to Ciba)
Orimeten Molecular Weight
232.278 g/mol
Orimeten Melting Point
149-150 oC
Orimeten H2O Solubility
Practically insoluble in water
Orimeten State
Solid
Orimeten LogP
2.029
Orimeten Dosage Forms
Tablet (250 mg)
Orimeten Indication
For the suppression of adrenal function in selected patients with Cushing's syndrome, malignant neoplasm of the female breast, and carcinoma in situ of the breast.
Orimeten Pharmacology
Aminoglutethimide inhibits the enzymatic conversion of cholesterol to D5-pregnenolone, resulting in a decrease in the production of adrenal glucocorticoids, mineralocorticoids, estrogens, and androgens.
Orimeten Absorption
Rapidly and completely absorbed from gastrointestinal tract. The bioavailability of tablets is equivalent to equal doses given as a solution.
Orimeten side effects and Toxicity
Oral LD50s (mg/kg): rats, 1800; dogs, >100. Intravenous LD50s (mg/kg): rats, 156; dogs, >100. Symptoms of overdose include respiratory depression, hypoventilation, hypotension, hypovolemic shock due to dehydration, somnolence, lethargy, coma, ataxia, dizziness, fatigue, nausea, and vomiting.
Orimeten Patient Information
Orimeten Organisms Affected
Humans and other mammals
